In order to assure tissue oxygenation in critically ill patients, normal practise calls for cardiac output monitoring, which has traditionally been carried out via a pulmonary artery catheter. The effectiveness of PAC, however, has been under scrutiny recently, with some arguing that its use may not only be unnecessary but also potentially detrimental.
This idea has significantly reduced the PAC’s widespread use, along with the availability of new, less intrusive cardiac output measuring devices. The ability to monitor or estimate cardiac output using a variety of technologies is now possible.
Some of these less intrusive tools give dynamic fluid responsiveness metrics and continually track stroke volume, While some offer continuous evaluation of central venous saturation using specialised catheters connected to the same monitor, others allow assessment of volumetric preload factors.
All of these factors, along with cardiac output, may lead to a more accurate assessment of the critically ill patient’s hemodynamics. Every device has inherent limits, though, and no cardiac output monitoring device can alter patient outcomes unless its use is combined with an intervention that has been shown to enhance patient outcomes on its own.
As a result, the idea of hemodynamic optimisation is becoming more widely accepted as a pillar in the care of critically sick patients and has been linked to better outcomes in both the perioperative and intensive care unit settings.
GLOBAL CARDIAC OUTPUT MONITORING SENSOR MARKET SIZE AND FORECAST
The Global Cardiac Output Monitoring Sensor market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
NEW PRODUCT LAUNCH
The new Reliant 2.0 system has been launched by Cheetah Medical, a supplier of noninvasive cardiac output and hemodynamic monitoring solutions. The Reliant 2.0 adds new parameters to provide a comprehensive suite of information for hemodynamic monitoring without the need for invasive modalities with the associated potential costs and risks, the company claimed.
These new parameters are in addition to core hemodynamic parameters such as cardiac output, cardiac index, and stroke volume. The updated parameters now include changes in thoracic fluid volume, noninvasive blood pressure, total peripheral resistance, stroke volume variation, and cardiac power.
The company claims that Cheetah’s patented Bioreactance Technology, which has been used successfully in over 2,000 patients in a variety of clinical settings including medical and surgical intensive care, perioperative care, emergency medicine, heart failure, hemodialysis, and exercise testing, powers the Reliant hemodynamic monitoring platform.
THIS REPORT WILL ANSWER FOLLOWING QUESTIONS
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.